1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Celator Claims Phase III Vyxeos Victory In AML

 
• By Mandy Jackson

Celator Pharmaceuticals Inc. more than quadrupled in after-hours trading on March 14 after the company reported Phase III overall survival (OS) data for Vyxeos (CPX-351) that could support US and EU approvals for the first new acute myeloid leukemia (AML) therapy in almost 40 years.

Celator Pharmaceuticals Inc. more than quadrupled in after-hours trading on March 14 after the company reported Phase III overall survival (OS) data for Vyxeos (CPX-351) that could support US and EU approvals for the first new acute myeloid leukemia (AML) therapy in almost 40 years.

Median OS for high-risk (secondary) AML patients treated with Vyxeos, which is a lyposomal formulation of a 5:1 ratio of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Sanofi Revels In More Positive Rilzabrutinib Data

 
• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

BioNTech To Buy mRNA Rivals CureVac

 
• By Andrew McConaghie

The $1.25bn buyout is a simple deal for BioNTech, bringing new mRNA R&D and manufacturing capacity while also ending a bothersome patent dispute.

Is Zydus’s Agenus Deal Opportunistic Or Strategic?

 
• By Vibha Ravi

Will Zydus’s acquisition and licensing deal with Agenus turn out to be a strategic move towards building an oncology portfolio or an opportunistic one driven by a venture capital mindset?